首页 > 最新文献

Expert Opinion on Drug Safety最新文献

英文 中文
Safety concerns of aztreonam: a real-world disproportionality analysis based on FDA adverse event reporting system. 阿曲南安的安全性问题:基于美国食品药品管理局不良事件报告系统的真实世界比例失调分析。
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-20 DOI: 10.1080/14740338.2024.2430307
Li-Li Cai, Hong Zhou, Na-Mei Wu, Li-Mian Hong, Zhi-Hang Lin

Background: Aztreonam was approved by the FDA for treating Gram-negative infections, including metallo-β-lactamase producers. This study extensively evaluated aztreonam-related adverse events (AEs) from the FDA Adverse Event Reporting System (FAERS) database for a better understanding of toxicities.

Methods: The signals of aztreonam-related AEs were quantified using disproportionality analyses, like reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker algorithms.

Results: Among the 18,182,912 records retrieved from the FAERS 11,627 cases were identified where aztreonam was the primary suspect drug. A total of 127 preferred terms with significant disproportionality that simultaneously met the criteria of all algorithms were retained. Unexpected safety signals such as cholestatic liver injury, hypoprothrombinemia, hemoptysis, pulmonary hemorrhage, drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis and so on may also manifest in adults, particularly in elderly patients. The median onset time for AEs related to intravenous aztreonam was 4 days, compared to a year after the initiation of inhaled aztreonam.

Conclusions: Our study identified potential new adverse event signals and offered a thorough understanding of aztreonam's safety profiles. This information is crucial for enhanced clinical monitoring and risk assessment, aiding healthcare professionals in tailoring their approach.

背景:美国食品药品管理局批准阿曲霉素用于治疗革兰氏阴性菌感染,包括金属-β-内酰胺酶产生者。本研究广泛评估了FDA不良事件报告系统(FAERS)数据库中与阿曲霉素相关的不良事件(AEs),以更好地了解其毒性:方法:使用报告几率比、报告比例比、贝叶斯置信度传播神经网络和多项目伽马泊松收缩器算法等不相称分析方法对阿曲霉素相关不良事件的信号进行量化:结果:从 FAERS 检索到的 18,182,912 条记录中,有 11,627 个病例的主要可疑药物是阿兹曲南。共保留了 127 个同时符合所有算法标准的具有显著比例失调的首选术语。胆汁淤积性肝损伤、低凝血酶原血症、咯血、肺出血、伴有嗜酸性粒细胞增多和全身症状的药物反应、急性全身泛发性脓疱病等意外安全信号也可能在成人,尤其是老年患者中出现。与静脉注射阿曲南有关联的不良反应的中位发病时间为4天,而吸入阿曲南则需要一年:我们的研究发现了潜在的新不良事件信号,并对阿兹曲南的安全性有了全面的了解。这些信息对加强临床监测和风险评估至关重要,有助于医护人员调整治疗方法。
{"title":"Safety concerns of aztreonam: a real-world disproportionality analysis based on FDA adverse event reporting system.","authors":"Li-Li Cai, Hong Zhou, Na-Mei Wu, Li-Mian Hong, Zhi-Hang Lin","doi":"10.1080/14740338.2024.2430307","DOIUrl":"https://doi.org/10.1080/14740338.2024.2430307","url":null,"abstract":"<p><strong>Background: </strong>Aztreonam was approved by the FDA for treating Gram-negative infections, including metallo-β-lactamase producers. This study extensively evaluated aztreonam-related adverse events (AEs) from the FDA Adverse Event Reporting System (FAERS) database for a better understanding of toxicities.</p><p><strong>Methods: </strong>The signals of aztreonam-related AEs were quantified using disproportionality analyses, like reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker algorithms.</p><p><strong>Results: </strong>Among the 18,182,912 records retrieved from the FAERS 11,627 cases were identified where aztreonam was the primary suspect drug. A total of 127 preferred terms with significant disproportionality that simultaneously met the criteria of all algorithms were retained. Unexpected safety signals such as cholestatic liver injury, hypoprothrombinemia, hemoptysis, pulmonary hemorrhage, drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis and so on may also manifest in adults, particularly in elderly patients. The median onset time for AEs related to intravenous aztreonam was 4 days, compared to a year after the initiation of inhaled aztreonam.</p><p><strong>Conclusions: </strong>Our study identified potential new adverse event signals and offered a thorough understanding of aztreonam's safety profiles. This information is crucial for enhanced clinical monitoring and risk assessment, aiding healthcare professionals in tailoring their approach.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacovigilance insights into drug-induced cystitis: analysis of FDA data from 2004 to 2024. 药物警戒对药物性膀胱炎的启示:2004 年至 2024 年 FDA 数据分析。
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-19 DOI: 10.1080/14740338.2024.2431587
Fuchun Zheng, Xin Yang, Sheng Li, Yuyang Yuan, Zhipeng Wang, Situ Xiong, Bin Fu, Wei Liu, Qi Lu

Background: Drug-induced cystitis (DIC) significantly impacts patient quality of life and treatment outcomes. This study investigates the incidence and characteristics of DIC using data from the FDA Adverse Event Reporting System (FAERS).

Methods: We reviewed FAERS reports related to cystitis from Q1 2004 to Q1 2024, compiling a list of potential causative drugs. The top 50 drugs with the highest number of cystitis reports were ranked. Statistical disproportionality analyses, including Proportional Reporting Ratio (PRR) and Reporting Odds Ratio (ROR), were used to detect unusually high reporting frequencies of cystitis associated with specific drugs.

Results: From 17,703,515 FAERS reports spanning 2004-2024, 36399 involved cystitis. The majority of implicated drugs were antineoplastics. Busulfan, BCG, and mitomycin had the highest ROR and PRR values. Additionally, drugs such as defibrotide sodium, milrinone, and dyazide, which do not have cystitis listed on their labels, were identified, highlighting the need for increased clinical vigilance and awareness.

Conclusion: The findings underscore the importance of ongoing pharmacovigilance in identifying and characterizing DIC. Further clinical studies are warranted to validate these associations and to develop strategies for mitigating the risk of DIC, thereby improving patient safety and treatment outcomes.

背景:药物性膀胱炎(DIC)严重影响患者的生活质量和治疗效果。本研究利用 FDA 不良事件报告系统(FAERS)的数据调查了 DIC 的发生率和特征:我们回顾了 2004 年第一季度至 2024 年第一季度与膀胱炎相关的 FAERS 报告,编制了一份潜在致病药物清单。对膀胱炎报告数量最多的前 50 种药物进行了排名。统计比例失调分析(包括比例报告比 (PRR) 和报告几率比 (ROR))用于检测与特定药物相关的膀胱炎异常高报告频率:在2004-2024年的17703515份FAERS报告中,有36399份涉及膀胱炎。大多数相关药物为抗肿瘤药物。布舒芬、卡介苗和丝裂霉素的 ROR 和 PRR 值最高。此外,还发现了非布罗泰钠、米力农和达拉嗪等标签上未列出膀胱炎的药物,这凸显了提高临床警惕和认识的必要性:结论:研究结果强调了持续进行药物警戒对识别和描述 DIC 的重要性。有必要开展进一步的临床研究来验证这些关联,并制定降低 DIC 风险的策略,从而改善患者安全和治疗效果。
{"title":"Pharmacovigilance insights into drug-induced cystitis: analysis of FDA data from 2004 to 2024.","authors":"Fuchun Zheng, Xin Yang, Sheng Li, Yuyang Yuan, Zhipeng Wang, Situ Xiong, Bin Fu, Wei Liu, Qi Lu","doi":"10.1080/14740338.2024.2431587","DOIUrl":"10.1080/14740338.2024.2431587","url":null,"abstract":"<p><strong>Background: </strong>Drug-induced cystitis (DIC) significantly impacts patient quality of life and treatment outcomes. This study investigates the incidence and characteristics of DIC using data from the FDA Adverse Event Reporting System (FAERS).</p><p><strong>Methods: </strong>We reviewed FAERS reports related to cystitis from Q1 2004 to Q1 2024, compiling a list of potential causative drugs. The top 50 drugs with the highest number of cystitis reports were ranked. Statistical disproportionality analyses, including Proportional Reporting Ratio (PRR) and Reporting Odds Ratio (ROR), were used to detect unusually high reporting frequencies of cystitis associated with specific drugs.</p><p><strong>Results: </strong>From 17,703,515 FAERS reports spanning 2004-2024, 36399 involved cystitis. The majority of implicated drugs were antineoplastics. Busulfan, BCG, and mitomycin had the highest ROR and PRR values. Additionally, drugs such as defibrotide sodium, milrinone, and dyazide, which do not have cystitis listed on their labels, were identified, highlighting the need for increased clinical vigilance and awareness.</p><p><strong>Conclusion: </strong>The findings underscore the importance of ongoing pharmacovigilance in identifying and characterizing DIC. Further clinical studies are warranted to validate these associations and to develop strategies for mitigating the risk of DIC, thereby improving patient safety and treatment outcomes.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1-8"},"PeriodicalIF":3.0,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142643403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Increased reporting of accidental overdose with glucagon-like peptide-1 receptor agonists: a population-based study. 胰高血糖素样肽-1 受体激动剂意外用药过量报告的增加:一项基于人群的研究。
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-19 DOI: 10.1080/14740338.2024.2430306
Roger S McIntyre, Angela T H Kwan

Background: The use of online and/or compounding pharmacies to access glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increases the risk for prescription error (e.g. accidental overdose) especially in racial, ethnic, and socioeconomic disadvantaged groups.

Methods: We sought to evaluate accidental overdose associated with GLP-1 RAs submitted to the United States FDA Adverse Event Reporting System (FAERS). Case reports of accidental overdose reported to the FAERS were retrieved from Q4 2003 to Q1 2024 using OpenVigil 2.1. Disproportionality of accidental overdose was assessed using reporting odds ratio (ROR). Upper and lower 95% confidence intervals (CI) were calculated at an alpha level of 5%, where disproportionate reporting was considered when the lower 95% CI was greater than 1.0.

Results: We identified 3,348 reports of accidental overdose associated with GLP-1 RAs. The RORs were significant for all agents within the class (ROR range: 2.64-61.12, all p < 0.008), including semaglutide, dulaglutide, exenatide, liraglutide, and tirzepatide compared to niacin.

Conclusions: Inadequate access, availability, and affordability of GLP-1 RAs has contributed to the increased seeking via online and/or compounding pharmacies, and is associated with greater risk for prescription errors that differentially affect racial, ethnic, and socioeconomic vulnerable populations. Pharmacovigilance database analyses cannot establish causation only association.

背景:使用网上药店和/或复合药店购买胰高血糖素样肽-1 受体激动剂(GLP-1 RAs)会增加处方错误(如意外用药过量)的风险,尤其是在种族、民族和社会经济弱势群体中:我们试图评估向美国 FDA 不良事件报告系统 (FAERS) 提交的与 GLP-1 RA 相关的意外用药过量情况。使用 OpenVigil 2.1 检索了 2003 年第四季度至 2024 年第一季度向 FAERS 报告的意外用药过量病例报告。意外用药过量的比例失调采用报告几率比(ROR)进行评估。上、下95%置信区间(CI)按5%的α水平计算,当下95%CI大于1.0时,则认为报告不成比例:我们发现了 3,348 例与 GLP-1 RAs 相关的意外用药过量报告。该类药物中所有药物的 ROR 均有显著性(ROR 范围:2.64-61.12,均为 p):GLP-1 RAs 的可及性、可获得性和可负担性不足,导致越来越多的人通过网上和/或复合药房购买 GLP-1 RAs,这与处方错误的风险增加有关,而处方错误对种族、民族和社会经济弱势群体的影响各不相同。药物警戒数据库分析不能确定因果关系,只能确定关联关系。
{"title":"Increased reporting of accidental overdose with glucagon-like peptide-1 receptor agonists: a population-based study.","authors":"Roger S McIntyre, Angela T H Kwan","doi":"10.1080/14740338.2024.2430306","DOIUrl":"10.1080/14740338.2024.2430306","url":null,"abstract":"<p><strong>Background: </strong>The use of online and/or compounding pharmacies to access glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increases the risk for prescription error (e.g. accidental overdose) especially in racial, ethnic, and socioeconomic disadvantaged groups.</p><p><strong>Methods: </strong>We sought to evaluate accidental overdose associated with GLP-1 RAs submitted to the United States FDA Adverse Event Reporting System (FAERS). Case reports of accidental overdose reported to the FAERS were retrieved from Q4 2003 to Q1 2024 using OpenVigil 2.1. Disproportionality of accidental overdose was assessed using reporting odds ratio (ROR). Upper and lower 95% confidence intervals (CI) were calculated at an alpha level of 5%, where disproportionate reporting was considered when the lower 95% CI was greater than 1.0.</p><p><strong>Results: </strong>We identified 3,348 reports of accidental overdose associated with GLP-1 RAs. The RORs were significant for all agents within the class (ROR range: 2.64-61.12, all <i>p</i> < 0.008), including semaglutide, dulaglutide, exenatide, liraglutide, and tirzepatide compared to niacin.</p><p><strong>Conclusions: </strong>Inadequate access, availability, and affordability of GLP-1 RAs has contributed to the increased seeking via online and/or compounding pharmacies, and is associated with greater risk for prescription errors that differentially affect racial, ethnic, and socioeconomic vulnerable populations. Pharmacovigilance database analyses cannot establish causation only association.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1-6"},"PeriodicalIF":3.0,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Examining the safety of belimumab, especially in children: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database. 研究贝利木单抗的安全性,尤其是对儿童的安全性:对美国食品药品管理局不良事件报告系统(FAERS)数据库中真实世界药物警戒数据的分析。
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-19 DOI: 10.1080/14740338.2024.2430302
Mingming Li, Ziming Zheng, Jie Li, Cong Wang, Ruxu You

Background: Belimumab was approved in the US in 2019 for children with Systemic lupus erythematosus (SLE), making it the only medicine that can treat SLE in both adults and children. The authors retrospectively investigated adverse events (AEs) by data-mining a self-reported database.

Research design and methods: PRR, ROR, and BCPNN were used to assess the association between belimumab and AEs. The definition relied on system organ class (SOC) and preferred terms (PT) by the Medical Dictionary for Regulatory Activities (MedDRA).

Results: A total of 15,316,605 AE reports were retrieved from the FAERS database, and 19,832 AE reports were identified after the data cleaning process. Based on the disproportionality analysis at the PT level, depressive (N = 420), ill-defined disorder (N = 304), injection site hemorrhage (N = 297), lupus nephritis (N = 198), live birth (N = 96) and proteinuria (N = 77) had relatively higher frequencies than other AEs, suggesting that these AEs are more likely to occur in the real world for patients taking belimumab.

Conclusions: This study explores valuable potential AEs of belimumab at the SOC and PT levels, respectively. To provide a reference for decision-making on belimumab, including its use in children, and to promote rational clinical dosing.

背景:美国于2019年批准贝利木单抗用于治疗儿童系统性红斑狼疮(SLE)患者,使其成为唯一一种可同时治疗成人和儿童SLE的药物。作者通过对自我报告数据库进行数据挖掘,对不良事件(AEs)进行了回顾性调查:采用PRR、ROR和BCPNN评估贝利木单抗与AEs之间的关联。定义依赖于系统器官分类(SOC)和监管活动医学词典(MedDRA)的首选术语(PT):结果:从FAERS数据库中共检索到15,316,605份AE报告,经数据清理后确定了19,832份AE报告。根据PT水平的比例失调分析,抑郁(420例)、定义不清的疾病(304例)、注射部位出血(297例)、狼疮性肾炎(198例)、活产(96例)和蛋白尿(77例)的发生频率相对高于其他AE,表明在现实世界中服用贝利木单抗的患者更有可能发生这些AE:本研究分别从SOC和PT水平探讨了贝利木单抗潜在的有价值的AEs。为包括儿童用药在内的贝利木单抗决策提供参考,促进临床合理用药。
{"title":"Examining the safety of belimumab, especially in children: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database.","authors":"Mingming Li, Ziming Zheng, Jie Li, Cong Wang, Ruxu You","doi":"10.1080/14740338.2024.2430302","DOIUrl":"10.1080/14740338.2024.2430302","url":null,"abstract":"<p><strong>Background: </strong>Belimumab was approved in the US in 2019 for children with Systemic lupus erythematosus (SLE), making it the only medicine that can treat SLE in both adults and children. The authors retrospectively investigated adverse events (AEs) by data-mining a self-reported database.</p><p><strong>Research design and methods: </strong>PRR, ROR, and BCPNN were used to assess the association between belimumab and AEs. The definition relied on system organ class (SOC) and preferred terms (PT) by the Medical Dictionary for Regulatory Activities (MedDRA).</p><p><strong>Results: </strong>A total of 15,316,605 AE reports were retrieved from the FAERS database, and 19,832 AE reports were identified after the data cleaning process. Based on the disproportionality analysis at the PT level, depressive (<i>N</i> = 420), ill-defined disorder (<i>N</i> = 304), injection site hemorrhage (<i>N</i> = 297), lupus nephritis (<i>N</i> = 198), live birth (<i>N</i> = 96) and proteinuria (<i>N</i> = 77) had relatively higher frequencies than other AEs, suggesting that these AEs are more likely to occur in the real world for patients taking belimumab.</p><p><strong>Conclusions: </strong>This study explores valuable potential AEs of belimumab at the SOC and PT levels, respectively. To provide a reference for decision-making on belimumab, including its use in children, and to promote rational clinical dosing.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mining and influencing factors analysis of sacituzumab govitecan adverse drug event based on FAERS database. 基于FAERS数据库的sacituzumab govitecan药物不良事件挖掘及影响因素分析。
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-19 DOI: 10.1080/14740338.2024.2430305
Liu Yang, Xueyu Duan, Shilin Wu, Xiaobo Liu, Hao Fan, Dingcai Zhang, Xuejiao Wu, Peng Hua

Objective: Utilizing the FAERS database, this study aims to analyze the ADE signals of sacituzumab govitecan to provide references for clinical safety.

Methods: By searching the US FAERS database, we applied Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR) methods to analyze ADE reports for sacituzumab govitecan from Q2 2020 to Q4 2023, covering 15 quarters.

Results: The total number of reports with sacituzumab govitecan as the first suspicion was 2854. A total of 139 signals involving 26 SOCs were obtained. The most reported were general disorders and administration site conditions (2,307 cases, 25.66%), followed by gastrointestinal disorders (1,125 cases, 12.52%), and investigations (810 cases, 9.01%). Frequent ADEs included sepsis and COVID-19 were not listed in the prescribing information. The signal strength analysis highlighted conditions like cholestasis and epilepsy not mentioned in the prescribing information. Furthermore, an analysis of influencing factors revealed differences in infections and infestations by gender and nationality (p < 0.05), and in gastrointestinal disorders and blood and lymphatic system disorders by gender, treatment duration, and nationality (p < 0.05).

Conclusions: Common ADEs generally correspond with the prescribing information. Clinicians should be vigilant regarding unlisted ADEs about sacituzumab govitecan, and close monitoring of laboratory indicators ensure patient medication safety.

研究目的本研究旨在利用FAERS数据库,分析sacituzumab govitecan的ADE信号,为临床安全性提供参考:通过检索美国FAERS数据库,采用报告比值比(ROR)和比例报告比(PRR)方法,分析了2020年第二季度至2023年第四季度,共15个季度的sacituzumab govitecan的ADE报告,并从影响因素层面分析了优先系统器官分类(SOC):结果:以sacituzumab govitecan为首要疑点的报告总数为2854份。共获得 139 个信号,涉及 26 个器官分类。报告最多的是一般疾病和用药部位状况(2307 例,25.66%),其次是胃肠道疾病(1125 例,12.52%)和检查(810 例,9.01%)。常见的 ADE 包括疾病进展和中性粒细胞减少症,而败血症和 COVID-19 等情况则未列入处方信息。信号强度分析强调了胆碱能综合征和三阴性乳腺癌等病症,而胆汁淤积症和癫痫等病症则未在处方信息中提及。此外,对影响因素的分析表明,不同性别和国籍的人在感染和侵袭方面存在差异(p p 结论):常见的 ADE 和涉及的器官系统一般与处方信息相符。临床医生在使用sacituzumab govitecan时应警惕未列出的ADEs,并密切监测实验室指标,确保患者用药安全。
{"title":"Mining and influencing factors analysis of sacituzumab govitecan adverse drug event based on FAERS database.","authors":"Liu Yang, Xueyu Duan, Shilin Wu, Xiaobo Liu, Hao Fan, Dingcai Zhang, Xuejiao Wu, Peng Hua","doi":"10.1080/14740338.2024.2430305","DOIUrl":"10.1080/14740338.2024.2430305","url":null,"abstract":"<p><strong>Objective: </strong>Utilizing the FAERS database, this study aims to analyze the ADE signals of sacituzumab govitecan to provide references for clinical safety.</p><p><strong>Methods: </strong>By searching the US FAERS database, we applied Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR) methods to analyze ADE reports for sacituzumab govitecan from Q2 2020 to Q4 2023, covering 15 quarters.</p><p><strong>Results: </strong>The total number of reports with sacituzumab govitecan as the first suspicion was 2854. A total of 139 signals involving 26 SOCs were obtained. The most reported were general disorders and administration site conditions (2,307 cases, 25.66%), followed by gastrointestinal disorders (1,125 cases, 12.52%), and investigations (810 cases, 9.01%). Frequent ADEs included sepsis and COVID-19 were not listed in the prescribing information. The signal strength analysis highlighted conditions like cholestasis and epilepsy not mentioned in the prescribing information. Furthermore, an analysis of influencing factors revealed differences in infections and infestations by gender and nationality (<i>p</i> < 0.05), and in gastrointestinal disorders and blood and lymphatic system disorders by gender, treatment duration, and nationality (<i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>Common ADEs generally correspond with the prescribing information. Clinicians should be vigilant regarding unlisted ADEs about sacituzumab govitecan, and close monitoring of laboratory indicators ensure patient medication safety.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1-10"},"PeriodicalIF":3.0,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preserving residual kidney function in persons on peritoneal dialysis: the role of pharmacotherapy. 保留腹膜透析患者的残余肾功能:药物疗法的作用。
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-18 DOI: 10.1080/14740338.2024.2431578
Reuben Formosa, Dustin Balzan, Stephen Falzon, Emanuel Farrugia, Janet Sultana
{"title":"Preserving residual kidney function in persons on peritoneal dialysis: the role of pharmacotherapy.","authors":"Reuben Formosa, Dustin Balzan, Stephen Falzon, Emanuel Farrugia, Janet Sultana","doi":"10.1080/14740338.2024.2431578","DOIUrl":"https://doi.org/10.1080/14740338.2024.2431578","url":null,"abstract":"","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiovascular outcomes of urate-lowering therapies in patients with gout or hyperuricemia: a network meta-analysis. 痛风或高尿酸血症患者降尿酸治疗对心血管的影响:一项网络荟萃分析。
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-18 DOI: 10.1080/14740338.2024.2430304
Yilong Yan, Ying Bai, Jiawei Wang, Guangyao Li

Background: To evaluate the comparative cardiovascular safety of urate-lowering therapies (ULTs) in patients with gout or hyperuricemia.

Research design and methods: Randomized controlled trials (RCTs) for ULTs with reported cardiovascular outcomes were included. Pairwise and network random-effect meta-analyses were performed to obtain the odds ratios (ORs) with 95% confidence intervals (CIs). The surface under the cumulative ranking curve (SUCRA) was employed to assess and rank the cardiovascular safety of ULTs.

Results: A total of 3,663 literature were retrieved, of which 26 RCTs involving 25,329 patients were finally included. Pairwise and network meta-analyses showed that allopurinol demonstrated a significant reduction in arrhythmia compared with febuxostat (for pairwise meta-analysis, OR = 0.69, 95%CI 0.49 to 0.97; for network meta-analysis, OR = 0.71, 95%CI 0.51 to 0.99). Nevertheless, there was no statistically significant difference observed in other outcomes between different ULTs or between ULTs and placebo (p > 0.05). According to the SUCRA, febuxostat and pegloticase, had the highest probability of mitigating the occurrence of major adverse cardiovascular events (MACEs) and all-cause mortality respectively.

Conclusions: Overall, ULTs showed relatively good cardiovascular safety in patients with gout or hyperuricemia. However, febuxostat has a higher risk of arrhythmia compared with allopurinol. Further studies are needed to confirm our findings.

研究背景评估痛风或高尿酸血症患者使用降尿酸盐疗法(ULT)对心血管安全性的比较:研究设计:纳入了有心血管结果报告的ULT随机对照试验(RCT)。通过配对分析和网络随机效应荟萃分析,得出几率比(OR)及95%置信区间(CI)。采用累积排序曲线下表面(SUCRA)对超短波治疗的心血管安全性进行评估和排序:结果:共检索到 3,663 篇文献,最终纳入了 26 项 RCT,涉及 25,329 名患者。配对荟萃分析和网络荟萃分析显示,与非布司他相比,别嘌醇可显著减少心律失常的发生(配对荟萃分析中,OR=0.69,95%CI为0.49至0.97;网络荟萃分析中,OR=0.71,95%CI为0.51至0.99)。不过,在其他结果方面,不同超短波治疗仪之间或超短波治疗仪与安慰剂之间均未观察到显著的统计学差异(P > 0.05)。根据SUCRA,非布索坦和培罗替酶分别最有可能减轻主要不良心血管事件(MACE)和全因死亡率的发生:总体而言,超低密度脂蛋白胆固醇类药物对痛风或高尿酸血症患者的心血管安全性相对较好。然而,与别嘌醇相比,非布索坦发生心律失常的风险更高。还需要进一步的研究来证实我们的发现。
{"title":"Cardiovascular outcomes of urate-lowering therapies in patients with gout or hyperuricemia: a network meta-analysis.","authors":"Yilong Yan, Ying Bai, Jiawei Wang, Guangyao Li","doi":"10.1080/14740338.2024.2430304","DOIUrl":"10.1080/14740338.2024.2430304","url":null,"abstract":"<p><strong>Background: </strong>To evaluate the comparative cardiovascular safety of urate-lowering therapies (ULTs) in patients with gout or hyperuricemia.</p><p><strong>Research design and methods: </strong>Randomized controlled trials (RCTs) for ULTs with reported cardiovascular outcomes were included. Pairwise and network random-effect meta-analyses were performed to obtain the odds ratios (ORs) with 95% confidence intervals (CIs). The surface under the cumulative ranking curve (SUCRA) was employed to assess and rank the cardiovascular safety of ULTs.</p><p><strong>Results: </strong>A total of 3,663 literature were retrieved, of which 26 RCTs involving 25,329 patients were finally included. Pairwise and network meta-analyses showed that allopurinol demonstrated a significant reduction in arrhythmia compared with febuxostat (for pairwise meta-analysis, OR = 0.69, 95%CI 0.49 to 0.97; for network meta-analysis, OR = 0.71, 95%CI 0.51 to 0.99). Nevertheless, there was no statistically significant difference observed in other outcomes between different ULTs or between ULTs and placebo (<i>p</i> > 0.05). According to the SUCRA, febuxostat and pegloticase, had the highest probability of mitigating the occurrence of major adverse cardiovascular events (MACEs) and all-cause mortality respectively.</p><p><strong>Conclusions: </strong>Overall, ULTs showed relatively good cardiovascular safety in patients with gout or hyperuricemia. However, febuxostat has a higher risk of arrhythmia compared with allopurinol. Further studies are needed to confirm our findings.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1-9"},"PeriodicalIF":3.0,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety assessment of cabozantinib in patients with renal cell carcinoma: retrospective pharmacovigilance study based on FAERS database. 卡博替尼对肾细胞癌患者的安全性评估:基于FAERS数据库的回顾性药物警戒研究。
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-17 DOI: 10.1080/14740338.2024.2429475
Zhipeng Wang, Fuchun Zheng, Liangwei Wan, Lei Zhang, Situ Xiong, Sheng Li, Chen Wang, Xiaoqiang Liu, Jun Deng

Objective: This study was designed to conduct data mining through the Food and Drug Administration Adverse Event Reporting System (FAERS) to assess adverse events (AEs) associated with cabozantinib in the treatment of renal cell carcinoma.

Methods: Reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS) algorithms were used to detect drug-related AEs signals from reporting data in FAERS database from 2016 to 2024.

Results: A total of 32,129 AE reports identifying cabozantinib as a 'primary suspect' were retrieved from the FAERS database. Among them, there were 21,549 reports of renal cell carcinoma as an indication. AEs induced by cabozantinib were observed in 23 system organ classes (SOCs). 215 AE signals were detected in 16 SOCs after four algorithms were simultaneously met. Among them, signals related to gastrointestinal disorders, general disorders and administration site conditions, and skin and subcutaneous tissue disorders were the most common. Of note, the median time to onset of AEs was 38 days (interquartile range (IQR) 14-116 days).

Conclusion: This study provides new insights into the monitoring, surveillance, and management of cabozantinib-related adverse drug reactions and provides a comprehensive long-term post-marketing safety assessment of cabozantinib.

研究目的本研究旨在通过食品药品管理局不良事件报告系统(FAERS)进行数据挖掘,以评估卡博替尼治疗肾细胞癌的相关不良事件(AEs):采用报告几率比(ROR)、比例报告比(PRR)、贝叶斯置信度传播神经网络(BCPNN)和多项目伽马泊松收缩器(MGPS)算法,从FAERS数据库2016年至2024年的报告数据中检测与药物相关的AEs信号:结果:从FAERS数据库中共检索到32129份将卡博替尼确定为 "主要嫌疑人 "的AE报告。其中,以肾细胞癌为适应症的报告有21549份。在23个系统器官类别(SOC)中观察到了卡博替尼所诱发的AE。同时满足四种算法后,在 16 个 SOC 中检测到 215 个 AE 信号。其中,与胃肠道功能紊乱、全身功能紊乱和用药部位状况以及皮肤和皮下组织功能紊乱相关的信号最为常见。值得注意的是,发生 AEs 的中位时间为 38 天(四分位距(IQR)为 14-116 天):本研究为卡博替尼相关药物不良反应的监测、监控和管理提供了新的见解,并对卡博替尼上市后的长期安全性进行了全面评估。
{"title":"Safety assessment of cabozantinib in patients with renal cell carcinoma: retrospective pharmacovigilance study based on FAERS database.","authors":"Zhipeng Wang, Fuchun Zheng, Liangwei Wan, Lei Zhang, Situ Xiong, Sheng Li, Chen Wang, Xiaoqiang Liu, Jun Deng","doi":"10.1080/14740338.2024.2429475","DOIUrl":"10.1080/14740338.2024.2429475","url":null,"abstract":"<p><strong>Objective: </strong>This study was designed to conduct data mining through the Food and Drug Administration Adverse Event Reporting System (FAERS) to assess adverse events (AEs) associated with cabozantinib in the treatment of renal cell carcinoma.</p><p><strong>Methods: </strong>Reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS) algorithms were used to detect drug-related AEs signals from reporting data in FAERS database from 2016 to 2024.</p><p><strong>Results: </strong>A total of 32,129 AE reports identifying cabozantinib as a 'primary suspect' were retrieved from the FAERS database. Among them, there were 21,549 reports of renal cell carcinoma as an indication. AEs induced by cabozantinib were observed in 23 system organ classes (SOCs). 215 AE signals were detected in 16 SOCs after four algorithms were simultaneously met. Among them, signals related to gastrointestinal disorders, general disorders and administration site conditions, and skin and subcutaneous tissue disorders were the most common. Of note, the median time to onset of AEs was 38 days (interquartile range (IQR) 14-116 days).</p><p><strong>Conclusion: </strong>This study provides new insights into the monitoring, surveillance, and management of cabozantinib-related adverse drug reactions and provides a comprehensive long-term post-marketing safety assessment of cabozantinib.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1-7"},"PeriodicalIF":3.0,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adverse events associated with aromatase inhibitors: an analysis of real-world datasets and drug-gene interaction network. 与芳香化酶抑制剂相关的不良事件:真实世界数据集和药物基因相互作用网络分析》。
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-11 DOI: 10.1080/14740338.2024.2424443
Si-Qi Zhang, Shujing Jia, Xiang Li, Rui-Rui Hu, Zhanyang Luo, Junhai Wang, Hongyan Xi

Background: Aromatase inhibitors (AIs) are commonly used to treat postmenopausal hormone receptor positive breast cancer, but there is currently a lack of comprehensive safety reports on AIs in large-scale cohorts.

Research design and methods: We conducted a retrospective pharmacovigilance survey based on the FDA Adverse Event Reporting System, retrieving relevant reports from the 2004 to the 2023, aiming to conduct a comprehensive comparative analysis of adverse reactions associated with AIs. In addition, we elucidated the potential toxicological mechanisms of AIs related adverse events through functional enrichment analysis.

Results: A total of 7,933 adverse event reports related to AIs were collected, and there were 642 positive signals at the preferred term level. The top three signal intensities for anastrozole are: antiphospholipid syndrome, plantar fasciitis and autoimmune pancreatitis. The top three signal intensities for letrozole are: androgenetic alopecia and myosclerosis, pneumonic herpes virus. The top three signal intensities for exemestane are: infection reactivation, thyroxine free decreased and dilatation atrial. In terms of onset time, letrozole has the earliest onset time overall, followed by exemestane, and finally anastrozole.

Conclusions: Our research corroborates the typical adverse events linked to AIs while highlighting potential safety concerns in their real-world clinical application.

背景:芳香化酶抑制剂(AIs)是治疗绝经后激素受体阳性乳腺癌的常用药物,但目前缺乏大规模队列中关于AIs的全面安全性报告:我们基于美国食品药品管理局的不良事件报告系统进行了一项回顾性药物警戒调查,检索了从 2004 年第一季度到 2023 年第三季度的相关报告,旨在对临床实践中常用人工合成药物的相关不良反应进行全面的比较分析。不良事件信号采用不成比例分析法进行评估。此外,我们还通过对与人工合成药物相互作用的人类基因进行功能富集分析,阐明了芳香化酶抑制剂相关不良反应的潜在毒理学机制:结果:共收集了 7,933 份与 AIs 相关的不良事件报告,其中有 642 个首选术语级别的阳性信号。阿那曲唑的前三个信号强度分别是:抗磷脂综合征、足底筋膜炎和自身免疫性胰腺炎。来曲唑的前三位信号强度是:雄激素性脱发和肌硬化症、肺疱疹病毒。依西美坦的前三位信号强度是:感染再激活、游离甲状腺素减少和心房扩张。从发病时间来看,来曲唑的发病时间最早,其次是依西美坦,最后是阿那曲唑:我们的研究证实了与人工合成药物相关的典型不良事件,同时强调了在实际临床应用中可能存在的安全问题。
{"title":"Adverse events associated with aromatase inhibitors: an analysis of real-world datasets and drug-gene interaction network.","authors":"Si-Qi Zhang, Shujing Jia, Xiang Li, Rui-Rui Hu, Zhanyang Luo, Junhai Wang, Hongyan Xi","doi":"10.1080/14740338.2024.2424443","DOIUrl":"10.1080/14740338.2024.2424443","url":null,"abstract":"<p><strong>Background: </strong>Aromatase inhibitors (AIs) are commonly used to treat postmenopausal hormone receptor positive breast cancer, but there is currently a lack of comprehensive safety reports on AIs in large-scale cohorts.</p><p><strong>Research design and methods: </strong>We conducted a retrospective pharmacovigilance survey based on the FDA Adverse Event Reporting System, retrieving relevant reports from the 2004 to the 2023, aiming to conduct a comprehensive comparative analysis of adverse reactions associated with AIs. In addition, we elucidated the potential toxicological mechanisms of AIs related adverse events through functional enrichment analysis.</p><p><strong>Results: </strong>A total of 7,933 adverse event reports related to AIs were collected, and there were 642 positive signals at the preferred term level. The top three signal intensities for anastrozole are: antiphospholipid syndrome, plantar fasciitis and autoimmune pancreatitis. The top three signal intensities for letrozole are: androgenetic alopecia and myosclerosis, pneumonic herpes virus. The top three signal intensities for exemestane are: infection reactivation, thyroxine free decreased and dilatation atrial. In terms of onset time, letrozole has the earliest onset time overall, followed by exemestane, and finally anastrozole.</p><p><strong>Conclusions: </strong>Our research corroborates the typical adverse events linked to AIs while highlighting potential safety concerns in their real-world clinical application.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1-10"},"PeriodicalIF":3.0,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142575642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world analysis of levetiracetam-associated rhabdomyolysis: insights from the FDA adverse event reporting system. 左乙拉西坦相关横纹肌溶解症的真实世界分析:美国食品药品管理局不良事件报告系统的启示。
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-08 DOI: 10.1080/14740338.2024.2421340
Guo Yinan, Gong Guangming, Guo Guangyu, Cheng Xianghai, Yin Jingwen, Qin Jie

Background: Levetiracetam, a widely prescribed antiseizure medication, is recognized for its broad-spectrum efficacy, good tolerability, and minimal drug interactions. This study examines the association between levetiracetam and rhabdomyolysis, utilizing real-world data from the FDA Adverse Event Reporting System (FAERS) database to further elucidate its safety profile.

Methods: This study extracted adverse events related to levetiracetam from the FAERS database (Q1 2013 to Q1 2024). Four types of disproportionality analysis identified rhabdomyolysis as a significant adverse event. Logistic regression assessed risk factors, including gender, age, and severity. A Gaussian Mixture Model analyzed the time-to-onset distribution of rhabdomyolysis, while the impact of concomitant medications on its risk was evaluated using Reporting Odds Ratio (ROR).

Results: Levetiracetam significantly increased rhabdomyolysis risk (ROR = 13.5). Males showed a higher incidence (OR = 2.60). Most adverse events occurred within the first 30 days, with a bimodal onset distribution. Co-administration of antibiotics, antipsychotics, and PPIs elevated the risk while other antiseizure medications did not.

Conclusion: This study found a significant association between levetiracetam and the risk of rhabdomyolysis, highlighting the need for increased clinical vigilance in this patient population. Future research should focus on elucidating the underlying mechanisms and optimizing clinical guidelines.

背景:左乙拉西坦是一种广泛处方的抗癫痫药物,因其广谱的疗效、良好的耐受性和极少的药物相互作用而广受认可。本研究利用FDA不良事件报告系统(FAERS)数据库中的真实数据,探讨了左乙拉西坦与横纹肌溶解症之间的关联,以进一步阐明其安全性:本研究从FAERS数据库(2013年第一季度至2024年第一季度)中提取了与左乙拉西坦相关的不良事件。四种比例失调分析确定横纹肌溶解症是一种重要的不良事件。逻辑回归评估了风险因素,包括性别、年龄和严重程度。高斯混合模型分析了横纹肌溶解症的发病时间分布,同时使用报告比值比(ROR)评估了伴随用药对其风险的影响:结果:左乙拉西坦显著增加横纹肌溶解风险(ROR = 13.5)。男性发病率更高(OR = 2.60)。大多数不良事件发生在最初的30天内,呈双峰分布。同时服用抗生素、抗精神病药和PPIs会增加风险,而其他抗癫痫药物则不会:本研究发现,左乙拉西坦与横纹肌溶解症的风险有明显关联,这突出表明临床上需要对这一患者群体提高警惕。未来的研究应侧重于阐明潜在机制和优化临床指南。
{"title":"Real-world analysis of levetiracetam-associated rhabdomyolysis: insights from the FDA adverse event reporting system.","authors":"Guo Yinan, Gong Guangming, Guo Guangyu, Cheng Xianghai, Yin Jingwen, Qin Jie","doi":"10.1080/14740338.2024.2421340","DOIUrl":"10.1080/14740338.2024.2421340","url":null,"abstract":"<p><strong>Background: </strong>Levetiracetam, a widely prescribed antiseizure medication, is recognized for its broad-spectrum efficacy, good tolerability, and minimal drug interactions. This study examines the association between levetiracetam and rhabdomyolysis, utilizing real-world data from the FDA Adverse Event Reporting System (FAERS) database to further elucidate its safety profile.</p><p><strong>Methods: </strong>This study extracted adverse events related to levetiracetam from the FAERS database (Q1 2013 to Q1 2024). Four types of disproportionality analysis identified rhabdomyolysis as a significant adverse event. Logistic regression assessed risk factors, including gender, age, and severity. A Gaussian Mixture Model analyzed the time-to-onset distribution of rhabdomyolysis, while the impact of concomitant medications on its risk was evaluated using Reporting Odds Ratio (ROR).</p><p><strong>Results: </strong>Levetiracetam significantly increased rhabdomyolysis risk (ROR = 13.5). Males showed a higher incidence (OR = 2.60). Most adverse events occurred within the first 30 days, with a bimodal onset distribution. Co-administration of antibiotics, antipsychotics, and PPIs elevated the risk while other antiseizure medications did not.</p><p><strong>Conclusion: </strong>This study found a significant association between levetiracetam and the risk of rhabdomyolysis, highlighting the need for increased clinical vigilance in this patient population. Future research should focus on elucidating the underlying mechanisms and optimizing clinical guidelines.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1-12"},"PeriodicalIF":3.0,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142497753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Expert Opinion on Drug Safety
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1